Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multicenter, Randomized, Double-Blind, 24-Week Study of the Clinical and Antiviral Effect of S-217622 Compared With Placebo in Non-Hospitalized Participants With COVID-19

Next Previous
Trial Profile

A Phase 3, Multicenter, Randomized, Double-Blind, 24-Week Study of the Clinical and Antiviral Effect of S-217622 Compared With Placebo in Non-Hospitalized Participants With COVID-19

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 18 Sep 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ensitrelvir (Primary)
  • Indications COVID 2019 infections
  • Focus Registrational; Therapeutic Use
  • Acronyms ACTIV-2d; SCORPIO-HR
  • Sponsors Shionogi

Most Recent Events

  • 03 Sep 2025 According to a Shionogi media release, data from this study will be presented at IDWeek 2025 (October 19-22, 2025) in Atlanta, Georgia.
  • 29 Oct 2024 According to a Shionogi media release, the data from this study were published in JAMA Network Open.
  • 23 Jul 2024 According to an AIDS Clinical Trials Group media release, the results form this trial will be presented at the AIDS 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top